» Articles » PMID: 39193025

Mesial Temporal Lobe Epilepsy and Hippocampal Sclerosis Associated with Mutant Neurons in the Cornu Ammonis: an Uncertain Pathogenesis and a Diagnostic Challenge

Overview
Specialty Neurology
Date 2024 Aug 28
PMID 39193025
Authors
Affiliations
Soon will be listed here.
Abstract

Mesial temporal lobe epilepsy (MTLE) is a common cause of seizures, and hippocampal sclerosis (HS) is the predominant subtype. mutations in MTLE-HS have only been reported infrequently. Herein, we illustrate the neurologic, radiological, and histopathological details of a patient with MTLE-HS and mutant neurons. A 31-year-old male with medically refractory epilepsy presented with magnetic resonance imaging (MRI) and electroencephalography (EEG) findings typical of mesial temporal sclerosis without a mass lesion. The surgical specimens showed ILAE Type 1 HS with neurons immunopositive for BRAFV600E mutant protein distributed along the Cornu Ammonis (CA) curvature. Instead of the normal mostly perpendicular orientation of pyramidal neurons relative to the hippocampal surface, the mutant neurons were often oriented in a parallel manner. On CD34 immunostaining, sparse clusters or nodules of CD34+ stellate cells and single immunopositive stellate cells were identified. BRAFV600E or CD34 immunopositive cells were less than 1 % of total cells. The patient responded well to surgery with no further seizures after 2 years and occasional auras. Hippocampal mutant non-expansive lesion (HBNL) has been used to describe such lesions with preserved cytoarchitecture and without overt tumor mass. Others may argue for the dual pathology of HS with early ganglioglioma. Whether pre-neoplastic lesions or early tumors, these cases are important for understanding early glioneuronal tumorigenesis and suggest that BRAFV600E studies should be routinely performed on MTLE-HS cases in the setting of clinical trials. With next-generation sequencing, a deletion was detected in almost half of the alleles in our case, suggesting that many of the histologically normal-appearing cells of the hippocampus contain this alteration. mutations can result in cytogenetic anomalies and defective DNA repair and therefore may underlie the development of a low frequency alteration.

References
1.
Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S . Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020; 395(10240):1835-1844. DOI: 10.1016/S0140-6736(20)30934-X. View

2.
Deb P, Sharma M, Tripathi M, Chandra P, Gupta A, Sarkar C . Expression of CD34 as a novel marker for glioneuronal lesions associated with chronic intractable epilepsy. Neuropathol Appl Neurobiol. 2006; 32(5):461-8. DOI: 10.1111/j.1365-2990.2006.00734.x. View

3.
Semah F, Lamy C, Demeret S . Hippocampal sclerosis and other hippocampal abnormalities in the early identification of candidates for epilepsy surgery. Arch Neurol. 2002; 59(6):1042-3; author reply 1043. DOI: 10.1001/archneur.59.6.1042-a. View

4.
Giulioni M, Marucci G, Cossu M, Tassi L, Bramerio M, Barba C . CD34 Expression in Low-Grade Epilepsy-Associated Tumors: Relationships with Clinicopathologic Features. World Neurosurg. 2018; 121:e761-e768. DOI: 10.1016/j.wneu.2018.09.212. View

5.
Goz R, Akgul G, LoTurco J . BRAFV600E expression in neural progenitors results in a hyperexcitable phenotype in neocortical pyramidal neurons. J Neurophysiol. 2020; 123(6):2449-2464. PMC: 7311733. DOI: 10.1152/jn.00523.2019. View